Phase 2 N=4 Sirolimus and Familial Adenomatous Polyposis (FAP)
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=171 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
Phase 2 N=63 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
Phase 3 N=58 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Familial Adenomatous Polyposis Coli · FAP
Primary: Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum. — -0.5; 0.5 Change from baseline number of polyps. — p=0.005
Phase 3 N=128 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
N/A N=44 Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
N/A N=607 The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants
Phase 2 N=92 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Adenomatous Polyposis Coli
Primary: Change in Duodenal Polyp Burden From Baseline to 6 Months — -8.5; 8.0 mm — p=<0.001
Phase 1 N=24 Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Change From Baseline to End of Study in Number of Rectal Polyps — -5.4; -1.6; -3.5 polyps — p=0.065
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
N/A N=71 A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Primary Safety Endpoint for This Study is the Composite Safety Endpoint (CSE) Defined as the Proportion of Patients With Early-onset and Late-onset Serious Adverse…
N/A N=28 Feeling and Body Investigators for Pediatric Abdominal Pain
Functional Abdominal Pain
Primary: Number of Participants Who Complete Treatment — 22 Participants
Phase 1 N=79 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Advanced Solid Tumors · Gastric Cancer · Transitional Cell Carcinoma of the Bladder
Primary: Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only). — 0; 0; 0; 0 Participants
N/A N=180 The FARAPULSE FARA-Freedom Trial
Paroxysmal Atrial Fibrillation
Primary: Effectiveness: Percentage of Participants Free of Chronic Treatment Failure Through 12 Months and Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial…
Phase 2 N=28 FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Locally Advanced Pancreatic Cancer · Pancreatic Cancer
Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
N/A N=30 A RWS of the FARAPULSE in A Chinese Population With PAF
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Acute Procedural Success — 30 Participants
N/A N=28 Feasibility Study of the FARAPULSE Endocardial Multi Ablation System in the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Safety at 30 Days — 1 Participants
Phase 2 N=44 Curcumin in Treating Patients With Familial Adenomatous Polyposis
Familial Adenomatous Polyposis
Primary: Polyp Number — 22.6; 18.6 polyps — p=0.58
Phase 2 N=25 BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Phase 2 N=28 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Alzheimer's Disease · Frontotemporal Dementia
Primary: Qualitative Amyloid Image Assessment — 2; 1; 8; 4 participants
N/A N=51 FACT Biomarker Subgroup Analysis
Pre-Eclampsia
Primary: Folate Status — 2701; 2686; 105; 67.1 nmol/L
Phase 2 N=14 Pilot Study of Metformin for Patients With Fanconi Anemia
Fanconi Anemia
Primary: Hematologic Response — 4 Participants
Phase 2 N=112 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Colorectal Cancer · Familial Adenomatous Polyposis
Primary: Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum — -1; -11; -1; -13 percentage change in polyp count
Phase 2 N=1,768 Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Alzheimer Disease · Mild Cognitive Impairment · Neurodegenerative Diseases
Primary: Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration — 21; 6; 5; 5 Participants
N/A N=10 PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Safety: Number of Participants With Prespecified Primary Safety Events Within 30 Days of Index Procedure. — 0 Participants
Phase 2 N=20 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-negative Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Best Overall Response — 5; 2 patients with progressive disease
Phase 1 N=99 Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Head and Neck Neoplasm · Prostatic Neoplasm · Pancreatic Neoplasm
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 3 N=243 Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
Colorectal Neoplasms · Trifluridine and Tipiracil · Circulating Tumor DNA
Primary: Disease-free Survival 1 (DFS1) — 9.30; 5.55 Months
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…